Loading...
OTCM
IMUC
Market cap25mUSD
Jul 09, Last price  
0.25USD
1D
27.26%
1Q
143.56%
Jan 2017
-98.76%
IPO
-99.94%
Name

Eom Pharmaceutical Holdings Inc

Chart & Performance

D1W1MN
OTCM:IMUC chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
22.92%
Rev. gr., 5y
%
Revenues
0k
00000300,00000000000000000
Net income
-2m
L+1.61%
0-246,004-5,152,713-3,614,753-3,059,730-2,626,205-6,150,142-5,719,903-14,495,139-8,750,161-9,392,560-12,924,719-23,397,538-18,516,568-1,452,992-2,679,170-2,646,904-1,612,737-1,892,133-1,922,557
CFO
-1m
L-44.25%
0-54,709-527,719-912,003-1,945,447-2,151,781-4,253,560-6,383,742-12,380,013-8,787,217-9,936,802-19,039,401-19,864,442-16,671,777-1,237,021-2,306,385-2,623,322-1,421,984-2,679,595-1,493,907

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medications. These treatments hold the potential to revolutionize existing therapeutic approaches. Among its key drug candidates currently undergoing development are EOM613 and EOM147. Established on March 20, 1987, the company maintains its corporate headquarters in Montvale, New Jersey.
IPO date
Sep 19, 2006
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT